Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAcuity RM Group plc Regulatory News (ACRM)

Share Price Information for Acuity RM Group plc (ACRM)

Share Price is delayed by 15 minutes
Get Live Data
0.725    0.00 (0.00%)
Bid:
0.70
Ask:
0.75
Spread: 0.05 (7.143%)
Market Cap: £1.77m
ACRM Live PriceLast checked at - London Stock Exchange

Intraday Acuity RM Group plc Share Chart

Issue of Equity

19 May 2025 09:45

Acuity RM Group Plc - Issue of Equity

Acuity RM Group Plc - Issue of Equity

PR Newswire

LONDON, United Kingdom, May 19

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

19 May 2025

 

Acuity RM Group plc

 

("Acuity" or the "Company")

 

Result of Placing and Subscription

 

Acuity RM Group plc (LSE: ACRM), the software group focused on cybersecurity confirms that, further to its announcement of 7:00 a.m. on 19 May 2025 that it has successfully closed the Placing and Subscription which raised in aggregate £0.41 million.

Capitalised terms used but not otherwise defined in this announcement shall have the meanings ascribed to such terms in Appendix II of the Company's announcement issued at 7:00 a.m. on 19 May 2025, unless the context requires otherwise.

Result of Placing and Subscription

Subject to the satisfaction of the conditions referred to below, the Placing has raised, in aggregate, gross proceeds of £368,571 through the placing of 36,857,143 new Ordinary Shares (the "Placing Shares") at a price of 1 pence per share (the "Issue Price"). The Subscription has raised £42,500 through the issue of 4,250,000 new Ordinary Shares at the Issue Price (the "Subscription Shares").

The allotment and issue of the Placing Shares and the Subscription Shares is conditional, inter alia, upon:

Admission becoming effective by no later than 8.00 a.m. on or around 23 May 2025 (or such other time and/or date, being no later than 8.00 a.m. on 6 June 2025, as the Joint Bookrunners and the Company may agree);the conditions in the Placing Agreement in respect of the Placing Shares being satisfied or (if applicable) waived; andthe Placing Agreement not having been terminated in accordance with its terms prior to Admission.

Accordingly, if any of such conditions are not satisfied or, if applicable, waived, the Placing and the Subscription will not proceed.

The Directors' Intended Subscription

As the Company is currently in a closed period under MAR until the announcement of its FY24 Results, the Directors are not permitted to subscribe for new Ordinary Shares until after announcement of the FY24 Results (and subject to each not being in possession of any other unpublished price sensitive information at such time).

All of the Directors and Simon Marvell, a co-founder of the business, intend to subscribe for, in aggregate, £105,000 through the issue of the Directors' Subscription Shares on the same terms as the Fundraising. Assuming that the Directors' Intended Subscription proceeds as contemplated, the Company will, therefore, apply for admission of the Directors' Subscription Shares to trading on AIM separately, to take effect following admission of the announcement of its FY24 Results. Further announcements will be made in respect of the Directors' Intended Subscription in due course.

Further issue of new Ordinary Shares

 

In August 2024 the Company acquired a loan note for a deferred consideration payable at 50 per cent. of any monies subsequently received pursuant to the loan note payable in cash or new Ordinary Shares at the Company's option. To date £10,000 has been received pursuant to the loan note and therefore the Company is paying consideration of £5,000 by way of the issue of 344,827 new Ordinary Shares at a price of 1.45 pence per share, being the mid-market price at close of business on 16 May 2025 (the "Loan Note Shares").

 

In addition, the Company has agreed to settle £16,261 of a supplier invoice by way of the issue of 1,121,454 new Ordinary Shares at a price of 1.45 pence per share (the "Supplier Shares"), being the closing mid-market price at closing of business on 16 May 2025.

 

The Warrants

The Company will also issue 41,107,143 Warrants to Placees and Subscribers in the Fundraising on the basis of one Warrant for every one New Ordinary Shares subscribed under the Fundraising. Each Warrant grants the holder the right to subscribe for one additional new Ordinary Share at a price of 1.5 pence per new Ordinary Share. The Warrants will not be traded on an exchange.

Broker Option

The Broker Option as described as described in the announcement issued at 7:00 a.m. on 19 May 2025 will remain open until 4:30pm on 20 May 2025.

To subscribe for Broker Option Shares, Existing Shareholders should communicate their bid to Peterhouse via their stockbroker as Peterhouse cannot take direct orders from individual private investors who are not existing clients. Existing Shareholders who wish to register their interest in participating in the Broker Option Shares should instruct their stockbroker to call Peterhouse on 020 7469 0938 or 020 7469 0936 or 020 7220 9797. Each bid should state the number of Broker Option Shares the Existing Shareholder wishes to subscribe for at the Issue Price.

Use of Proceeds

The net proceeds from the Placing, Subscription and Directors' Intended Subscription will be applied as follows:

£90k: sales and marketing£200k: new product developments£170k: working capital purposes

 

Admission and Total Voting Rights

Application has been made to the London Stock Exchange for admission of the Placing Shares, the Subscription Shares, the Loan Note Shares and the Supplier Shares, a total of 42,573,424 new Ordinary Shares to trading on AIM (the "New Shares"). It is expected that Admission will become effective and dealings in the New Shares will commence on AIM at 8.00 a.m. on or around 23 May 2025 (or such later date as may be agreed between the Company and the Joint Bookrunners, but no later than 6 June 2025) ("Admission").

The New Shares will be issued fully paid and will rank pari passu in all respects with the Company's existing Ordinary Shares.

The total number of Ordinary Shares in the capital of the Company following the issue of the Placing Shares, the Subscription Shares, the Loan Note Shares and the Supplier Shares will be 192,701,583 with voting rights. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company's share capital pursuant to the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

For further information, please contact:

For further information please contact:

 

Acuity RM Group plc

https://www.acuityrmgroup.com

Angus Forrest

+44 (0) 20 3582 0566

Zeus (NOMAD & Joint Broker)

https://www.zeuscapital.co.uk

Mike Coe / James Bavister

0203 829 5000

 

Peterhouse Capital (Joint broker)

 

Lucy Williams / Duncan Vasey

020 7469 0936

 

 

 

About Acuity RM Group:

Acuity RM Group plc (AIM: ACRM), is an established provider of risk management services. Its award-winning software platform, STREAM®, which collects and analyses data about organisations to improve business decisions and management, is used by around 60 organisations in markets including government, utilities, defence, broadcasting, manufacturing and healthcare.

The Company is focused on delivering long term, sustainable growth in shareholder value from organic growth and complementary acquisitions.

 

 



12
Date   Source Headline
23rd Jun 20267:00 amPRNResult of Oversubscribed Retail Offer
17th Jun 20267:00 amPRNRetail Offer
16th Jun 20264:33 pmRNSFundraise of approximately £400,000
8th Jun 20267:00 amRNS-RContract Expansion
24th Apr 20267:00 amPRNTrading Statement
23rd Apr 20267:00 amPRNTrading Statement
27th Mar 20267:00 amPRNIssue of Equity
16th Mar 20267:00 amRNSProduct Launch
16th Mar 20267:00 amPRNProduct Launch
9th Mar 20267:00 amRNS-RA client’s experience of Acuity
24th Feb 20267:00 amRNS-RContract win
17th Feb 20267:00 amPRNContract
5th Feb 20262:35 pmPRNDirector/PDMR Shareholding
5th Feb 20261:17 pmPRNPDMR Shareholding
4th Feb 20267:00 amPRNHolding in Company
2nd Feb 20267:00 amPRNContract
15th Jan 20268:07 pmPRNHoldings in Company and Director Dealing
15th Jan 20267:00 amPRNStatement re Investor Presentation 10.00am 21 January
13th Jan 20267:00 amPRNTrading Statement
18th Nov 20258:47 amRNSHolding(s) in Company
17th Nov 20257:00 amPRNStatement re sale of investment
13th Nov 20254:06 pmPRNHolding(s) in Company
12th Nov 20257:00 amPRNDirectorate changes
21st Oct 20257:00 amRNS-RContract Win
7th Oct 20257:00 amPRNContract
22nd Sep 20257:00 amPRNIssue of Equity
16th Sep 20251:03 pmPRNHolding(s) in Company
5th Sep 20257:00 amPRNStatement re Investor presentation 10.00am 11 September
2nd Sep 20257:00 amPRNHalf-year Report
18th Aug 20257:00 amRNS-RFirst customer win for new product
30th Jul 20251:52 pmPRNResult of AGM
29th Jul 20257:00 amPRNIssue of Equity
11th Jul 202511:33 amPRNHolding(s) in Company
7th Jul 20254:09 pmPRNAnnual Report and Notice of AGM
7th Jul 202512:23 pmPRNHolding(s) in Company
7th Jul 20257:00 amPRNProduct Launch
4th Jul 202511:56 amPRNHolding(s) in Company
2nd Jul 20257:00 amPRNStatement re Final Results
30th Jun 20251:54 pmPRNIssue of Equity
26th Jun 20256:04 pmPRNHolding(s) in Company
25th Jun 20259:30 amRNSFinal Results
19th Jun 20253:22 pmPRNHolding(s) in Company
13th Jun 202510:30 amPRNStatement re Business and Directorate
21st May 20257:00 amPRNIssue of Equity
19th May 20259:45 amPRNIssue of Equity
19th May 20257:00 amPRNIssue of Equity
6th Mar 20257:00 amPRNStatement re Investor Presentation
17th Feb 20257:00 amPRNDirector/PDMR Shareholding
7th Feb 20257:00 amPRNChanges in share options
5th Feb 20258:59 amPRNCorrection to Year end Update
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.